See What Happens Next, page-10

Yeah cheetah, sadly, it appears the company has no sense. Quite possibly revolutionary science from the Dish to MPACs, and I want to see management equal to the science. No sign of it yet. The current FDA mandates an out-of-the-box strategy, because Shoulson's insider strategy failed, completely. Nobody should be collecting paychecks at this point, because they failed, and have offered no viable alternative to failure so far.

Speculative small-cap pharma or not, they should be embarrassed to be trading at cash. I could train a monkey to destroy shareholder value as effectively as they have, and the monkey would do it for free. It's trading at cash because they have given no viable path to approval for PBT2, or any other drug in the pipeline. Management failure 101. There are posters on this board who have offered better strategy than the collective clown-act called Prana. Is it too much to ask ... oh, why bother at this point.